Partnership Opportunity Success TMS has an exclusive agreement to use Neuronetics’ NeuroStar platform for treatment-resistant MDD, presenting a potential joint sales angle with NeuroStar-related services or integration discussions for extended coverage and bundle offerings.

Clinical Expansion Position Success TMS as a rapidly growing TMS provider with a 8-week relief cycle and a claim of being the world’s second largest TMS provider, indicating opportunity to cross-sell to clinics or hospitals seeking scale and proven patient outcomes.

Financial Scale With reported annual revenue in the mid six-figure to low seven-figure range, there may be interest from investors or strategic buyers seeking additive revenue streams in neurohealth, as well as potential channel partnerships to accelerate growth.

Market Coverage Located in West Palm Beach with a multi-state health insurance and Medicare coverage claim for TMS, there is potential to target payers, Medicare Advantage plans, and regional health systems for expanded network inclusion and referral partnerships.

Leadership & Branding Key personnel changes, including the appointment of a COO, signal leadership stability and potential for sales campaigns that leverage executive visibility; craft high-level outreach that highlights governance, scaling capabilities, and value-based care outcomes.